natgillin/translations-raw huggingface dataset:
Farmakokinetická analýza populácie naznačila, že plazmatický klírens trabektedínu nie je ovplyvnený vekom (rozsah 19-83 rokov), pohlavím, celkovou telesnou hmotnoťou (v rozpätí 36 až 148 kg) alebo plochou povrchu tela (v rozpätí 0,9 až 2,8 m2).
A population pharmacokinetic analysis indicated that the plasma clearance of trabectedin is not influenced by age (range 19-83 years), gender, total body weight (range: 36 to 148 kg) or body surface area (range: 0.9 to 2.8 m2).
Farmakokinetické interakční studie se neprováděly, proto se užívání alli nedoporučuje u pacientů léčených akarbózou.
In the absence of pharmacokinetic interaction studies, alli is not recommended to be used by patients receiving acarbose.
Farmakokinetické vlastnosti
Pharmacokinetic properties
Farmakokinetické údaje týkající se užívání přípravku EVOTAZ u pacientů s poruchou funkce jater nejsou k dispozici.
There are no pharmacokinetic data regarding the use of EVOTAZ in patients with hepatic impairment.
Farmakokinetický profil trabektedínu je konzistentný s viacoddielovým dispozičným modelom.
Trabectedin pharmacokinetic profile is consistent with a multiple-compartment disposition model.
Farmakokinetika (PK) enkratnega in večkratnega odmerjanja zdravila Teysuno v kombinaciji s cisplatinom je bila ovrednotena v treh študijah.
The single and multiple dose pharmacokinetics (PK) of Teysuno in combination with cisplatin were evaluated in three studies.
Farmakokinetika aktivnega presnovka klopidogrela in njegovo antitrombocitno delovanje, merjeno s preskusi agregacije trombocitov ex vivo, se razlikuje glede na genotip CYP2C19.
Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype.
Farmakokinetika guanfacinu u dětských (ve věku 6 až 12 let) a dospívajících (ve věku 13 až 17 let) pacientů s ADHD a zdravých dospělých dobrovolníků je podobná.
The pharmacokinetics of guanfacine is similar in children (aged 6 to 12) and adolescent (aged 13 to 17) ADHD patients, and healthy adult volunteers.
Farmakokinetika pri posebnih populacijah
Pharmacokinetics in special populations
Farmakokinetika pri posebnih skupinah bolnikov
Pharmacokinetics in special populations
Farmakokinetika ustekinumaba je bila pri bolnikih s psoriazo azijskega in ne-azijskega porekla v glavnem primerljiva.
The pharmacokinetics of ustekinumab were generally comparable between Asian and non-Asian patients with psoriasis.
Farmakokinetiken för avibaktam har inte fastställts hos patienter för någon grad av nedsatt leverfunktion.
The pharmacokinetics of avibactam in patients with any degree of hepatic impairment has not been studied.
Farmakokinetiken för både ceftazidim och avibaktam är i stort sett linjär under det studerade dosintervallet (50 mg till 2 000 mg) vid en enstaka intravenös administrering.
The pharmacokinetics of both ceftazidime and avibactam are approximately linear across the dose range studied (50 mg to 2000 mg) for a single intravenous administration.
Farmakokinetiken för ceftarolin hos patienter med nedsatt leverfunktion har inte fastställts.
The pharmacokinetics of ceftaroline in patients with hepatic impairment has not been established.
Farmakokinetiken för ceftazidim har inte fastställts hos patienter med kraftigt nedsatt leverfunktion.
The pharmacokinetics of ceftazidime in patients with severe hepatic impairment has not been established.
Farmakokinetiken för ceftazidim/avibaktam påverkas inte nämnvärt av kön eller etnisk härkomst.
The pharmacokinetics of ceftazidime/avibactam is not significantly affected by gender or race.
Farmakokinetiken hos emtricitabin har inte studerats hos icke-HBV-infekterade individer med olika grader av leverinsufficiens.
The pharmacokinetics of emtricitabine have not been studied in non-HBV infected subjects with varying degrees of hepatic insufficiency.
Farmakokinetiken hos emtricitabin hos spädbarn, barn och ungdomar (från 4 månader upp till 18 år) liknade i allmänhet den som observerats hos vuxna.
In general, the pharmacokinetics of emtricitabine in infants, children and adolescents (aged 4 months up to 18 years) are similar to those seen in adults.
Farmakokinetiken hos emtricitabin är proportionell mot dosen i dosområdet 25 till 200 mg efter enstaka eller upprepad administrering.
The pharmacokinetics of emtricitabine are proportional to dose over the dose range of 25-200 mg following single or repeated administration.
Farmakokinetiko dušikovega oksida so raziskovali pri odraslih.
The pharmacokinetics of nitric oxide has been studied in adults.
Farmakokinetisk/farmakodynamisk relation
Pharmacokinetic/pharmacodynamic relationship
Farmakokinetiska data saknas på äldre (över 65 år).
Pharmacokinetic data are not available in the elderly (over 65 years of age).
Farmakokinetiska egenskaper
Pharmacokinetic particulars
Farmakokinetiska egenskaper
Pharmacokinetic properties
Farmakokinetiska parametrar bestämdes efter administrering av en singeldos av 200 mg emtricitabin hårda kapslar till 30 icke-hiv-infekterade individer med olika grader av njurinsufficiens.
Pharmacokinetic parameters were determined following administration of a single dose of 200 mg emtricitabine hard capsules to 30 non-HIV infected subjects with varying degrees of renal insufficiency.
Farmakokinetiske oplysninger
Pharmacokinetic particulars
Farmakokinetične informacije so navedene v poglavju 5.2.
Pharmacokinetic information is provided in section 5.2.
Farmakokinetične lastnosti
5.2 Pharmacokinetic properties
Farmakokinetične lastnosti
Pharmacokinetic properties
Farmakokinetične podatke o enkratnem odmerku i.v. danega palonosetrona so pridobili iz podskupine pediatričnih bolnikov z rakom (n=280), ki so prejeli 10 µg/kg ali 20 µg/kg.
Single-dose intravenous palonosetron pharmacokinetic data was obtained from a subset of paediatric cancer patients (n=280) that received 10 μg/kg or 20 μg/kg.
Farmakokinetične študije medsebojnega delovanja zdravila z drugimi zdravili in vivo pri ljudeh niso izvedli.
No in vivo human pharmacokinetic interaction studies have been performed.
Farmakokinetični podatki o bolnikih z zmanjšanim delovanjem ledvic ali jeter niso na voljo.
No pharmacokinetic data are available in patients with impaired renal or hepatic function.
Farmakokinetični profil za 5-FU je bil v prisotnosti in odsotnosti oteracila podoben.
The 5-FU pharmacokinetic profile was similar in the presence and absence of oteracil.
Farmakokinetičnih podatkov o bolnikih s hudo insuficienco ledvic (očistek kreatinina < 30 ml/min) je malo.
Only limited pharmacokinetic data are available in patients with severe renal insufficiency (creatinine clearance < 30 ml/min).
Farmakokinetičnih podatkov o zoledronski kislini pri bolnikih s hiperkalciemijo ali z insuficienco jeter ni.
No pharmacokinetic data for zoledronic acid are available in patients with hypercalcaemia or in patients with hepatic insufficiency.
Farmakokinetičnih študij z zdravilom Teysuno pri pediatrični populaciji niso opravili.
No pharmacokinetc studies have been conducted with Teysuno in paediatric patients.
Farmakologisk t aktivt ämne
Pharmacolo- gically active substance
FARMAKOLOOGILISED OMADUSED
PHARMACOLOGICAL PROPERTIES
FARMAKOLOŠKE LASTNOSTI
PHARMACOLOGICAL PARTICULARS
FARMAKOLOŠKE LASTNOSTI
PHARMACOLOGICAL PROPERTIES
FARMAKOLOŠKE LASTNOSTI Farmakodinamične lastnosti
PHARMACOLOGICAL PARTICULARS Pharmacodynamic properties
Farmakoterapeutická skupina: antihypertenziva, antiadrenergní látky, centrálně působící, ATC kód: C02AC02.
Pharmacotherapeutic group: Antihypertensives, antiadrenergic agents, centrally acting ATC code: C02AC02.
Farmakoterapeutická skupina: Antineoplastické činidlo, ATC kód: L01CX01.
Pharmacotherapeutic group: Antineoplastic agent, ATC code: L01CX01.
Farmakoterapeutická skupina: antivirotika pro systémovou aplikaci; antivirotika k léčbě HIV infekce, kombinace.
Pharmacotherapeutic group: Antivirals for systemic use; antivirals for treatment of HIV infections, combinations.
Farmakoterapeutická skupina: inhibitory agregace trombocytů kromě heparinu, ATC kód: B01AC-04.
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04.
Farmakoterapeutická skupina: přípravky k léčbě obezity, kromě dietetik, periferně působící přípravky k léčbě obezity, ATC kód A08AB01
Pharmacotherapeutic group: antiobesity preparations, excl. diet products, peripherally acting antiobesity products, ATC code A08AB01.
Farmakoterapeutická skupina: přípravky k léčbě obezity, kromě dietetik, periferně působící přípravky k léčbě obezity, ATC kód: A08AB01
Pharmaco-therapeutic group: antiobesity preparations, excl. diet products, peripherally acting antiobesity products, ATC code A08AB01.
Farmakoterapeutiline rühm: Seentevastased ained süsteemseks kasutamiseks, teised seentevastased ained, mis on mõeldud süsteemseks kasutamiseks, ATC-kood: J0AX05
Pharmacotherapeutic group: Antimycotics for systemic use, other antimycotics for systemic use, ATC code: J02AX05
Farmakoterapeutisk grupp: Antibakteriella medel för systemiskt bruk, ceftazidim, kombinationer, ATC-kod: J01DD52
Pharmacotherapeutic group: Antibacterials for systemic use, ceftazidime, combinations, ATC code: J01DD52
Farmakoterapeutisk grupp: antibakteriella medel för systemiskt bruk, övriga cefalosporiner, ATC-kod: J01DI02
Pharmacotherapeutic group: Antibacterials for systemic use, other cephalosporins, ATC code: J01DI02
Farmakoterapeutisk grupp: Antiemetika.
Pharmacotherapeutic group: Antiemetics.
Farmakoterapeutisk grupp: Antimykotika för systemiskt bruk, triazolderivat.
Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives.
Farmakoterapeutisk grupp: Omvända transkriptashämmare av nukleosid- och nukleotidtyp, ATC-kod: J05AF09
Pharmacotherapeutic group: Nucleoside and nucleotide reverse transcriptase inhibitors, ATC code: J05AF09
Farmakoterapeutisk gruppe: Immunologiske lægemidler til heste: levende bakteriel vaccine ATCvet-kode: QI05 AE
Pharmacotherapeutic group: immunological for equidae, live bacterial vaccine, ATCvet code: QI05AE.
Farmakoterapeutisk gruppe: Inaktiverede virale og bakterielle vacciner til svin.
Pharmacotherapeutic group: Inactivated viral and inactivated bacterial vaccines for pigs.
Farmakoterapevtska skupina: antineoplastična zdravila, antimetaboliti, oznaka ATC: L01BC53.
Pharmacotherapeutic group: antineoplastic agents, antimetabolites, ATC code: L01BC53.
Farmakoterapevtska skupina: antiparkinsoniki, agonisti dopamina, Oznaka ATC: N04BC05.
Pharmacotherapeutic group: anti-Parkinson drugs, dopamine agonists, ATC code: N04BC05.
Farmakoterapevtska skupina: druga zdravila z delovanjem na novotvorbe (citostatiki), oznaka ATC: L01XX17
Pharmacotherapeutic group: Other antineoplastic agents, ATC code: L01XX17.
Farmakoterapevtska skupina: kinolonske protimikrobne učinkovine Oznaka ATCvet: QJ 01 MA 96 Ibafloksacin je širokospektralen, baktericidni antibiotik.
Pharmacotherapeutic group: antibacterial quinolone ATCvet code: QJ 01 MA 96
Farmakoterapevtska skupina: kinolonske protimikrobne učinkovine Oznaka ATCvet: QJ 01 MA Zdravilna učinkovina v Ibaflinu je ibafloksacin.
Pharmacotherapeutic group: antibacterial quinolone ATCvet code: QJ 01 MA
Farmakoterapevtska skupina: protivnetna in protirevmatična zdravila, nesteroidna (oksikami) Oznaka ATCvet: QM01AC06
Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams), ATCvet code: QM01AC06
Farmakoterapevtska skupina: Senzibilizatorji, ki se uporabljajo za fotodinamično/obsevalno zdravljenje, oznaka ATC: L01X D01
Pharmacotherapeutic group: Sensitizers used in photodynamic/radiation therapy, ATC code: L01XD01
Farmakoterapevtska skupina: Senzibilizatorji, ki se uporabljajo za fotodinamično/obsevalno zdravljenje, oznaka ATC: L01XD01
Pharmacotherapeutic group: Sensitizers used in photodynamic/radiation therapy, ATC code: L01XD01‌
Farmakoterapevtska skupina: Učinkovine, ki vplivajo na lipide, zaviralci reduktaze hidroksimetilglutaril koencima A v kombinaciji z drugimi učinkovinami, ki vplivajo na lipide, oznaka ATC: C10BA03
Pharmacotherapeutic group: Lipid modifying agents, HMG CoA reductase inhibitors in combination with other lipid modifying agents, ATC code: C10BA03
Farmakoterapevtska skupina: Zaviralci agregacije trombocitov brez heparina Oznaka ATC: B01AC04
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04.
Farmakoterapevtska skupina: zdravila z delovanjem na novotvorbe, analogi folne kisline.
Pharmacotherapeutic group: antineoplastic agents, folic acid analogues.
Farmakoterapevtska skupina: zdravila za zdravljenje bolezni kosti, difosfonati, oznaka ATC: M05BA08
Pharmacotherapeutic group: Drugs for treatment of bone diseases, bisphosphonates, ATC code: M05BA08
FARMATSEUTILISED ANDMED
PHARMACEUTICAL PARTICULARS
Farnham Road, Bordon, Hampshire, GU35 0NF
Lion Court Farnham Road Bordon, Hampshire GU35 0NF
Farnham Road, Bordon, Hampshire, GU35 0NF Обединено кралство
Farnham Road, Bordon Hampshire, GU35 0NF United Kingdom
FAS
FAS PP
FAS-I: Подгрупа от FAS, която също е имала поне 1 епизод на инконтиненция в дневника на изходно ниво.
FAS-I: Subset of FAS who also had at least 1 incontinence episode in the baseline diary.
FAS: Цялата анализирана популация
FAS: Full analysis set
FAS: група за пълен анализ, всички рандомизирани пациенти, които са взели поне 1 доза от лекарствата в двойно сляпото проучване и които имат измерване на уринирането в дневника на изходно ниво и поне 1 измерване на уринирането в дневника за измерване на уринирането след изходното ниво
FAS: Full analysis set, all randomized patients who took at least 1 dose of double blind study drug and who had a micturition measurement in the baseline diary and at least 1 post-baseline visit diary with a micturition measurement.
FAS: група за пълен анализ, всички рандомизирани пациенти, които са взели поне 1 доза от лекарствата в двойно сляпото проучване и които имат измерване на уринирането в дневника на изходно ниво и поне 1 измерване на уринирането в дневника за измерване на уринирането след изходното ниво.
FAS: Full analysis set, all randomized patients who took at least 1 dose of double blind study drug and who had a micturition measurement in the baseline diary and at least 1 post-baseline visit diary with a micturition measurement.
FAS: група за пълен анализ, всички рандомизирани пациенти, които са взели поне 1 доза от лекарствата в двойносляпото проучване и които имат измерване на уринирането в дневника на изходно ниво и поне 1 измерване на уринирането в дневника за измерване на уринирането след изходното ниво.
FAS: Full analysis set, all randomized patients who took at least 1 dose of double blind study drug and who had a micturition measurement in the baseline diary and at least 1 post-baseline visit diary with a micturition measurement.
Faslodex 250 mg
Faslodex 250 mg (N=374)
Faslodex 250 mg инжекционен разтвор
Faslodex 250 mg solution for injection
Faslodex 250 mg инжекционен разтвор фулвестрант
Faslodex 250 mg solution for injection. fulvestrant
Faslodex 500 mg
Faslodex 500 mg (N=362)
Faslodex е бистър, безцветен до жълт вискозен разтвор в предварително напълнена спринцовка с капачка, защитена от отваряне, съдържаща 5 ml инжекционен разтвор.
Faslodex is a clear, colourless to yellow, viscous solution in a pre-filled syringe fitted with a tamper-evident closure, containing 5 ml solution for injection.
Faslodex е инжекционен разтвор, който съдържа активното вещество фулвестрант (fulvestrant).
Faslodex is a solution for injection that contains the active substance fulvestrant.
Faslodex е показан за лечение на постменоапаузални жени с естроген–рецептор позитивен локално авансирал или метастазирал рак на млечната жлеза при рецидив на заболяването по време на или след адювантна терапия с антиестрогенен препарат или при прогресия на заболяването по време на терапия с антиестроген.
Faslodex is indicated for the treatment of postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on therapy with an anti-estrogen.
Faslodex е противопоказен за жени, които могат да проявят свръхчувствителност (алергични реакции) към фулвестрант или някоя от другите съставки.
Faslodex should not be used in people who may be hypersensitive (allergic) to fulvestrant or any of the other ingredients.
Faslodex не е показан за употреба при деца и юноши под 18 години.
Faslodex is not indicated in children and adolescents under 18 years.
Faslodex се абсорбира бавно в тялото, като действието на всяка доза трае повече от месец.
Faslodex is absorbed slowly into the body, with the effects of each dose lasting over a month.
Faslodex се използва за лечение на локално инвазивен или метастазирал рак на гърдата при жени след менопауза,(жени, при които менопаузата е преминала).
Faslodex is used to treat locally advanced or metastatic breast cancer in women who have been through the menopause.
Faslodex се използва за лечение на напреднал или метастазирал рак на гърдата при жени в менопауза.
Faslodex is used to treat advanced or metastatic breast cancer in postmenopausal women.
Faslodex се предлага в два вида опаковки – или опаковка, съдържаща 1 стъклена предварително напълнена спринцовка, или опаковка, съдържаща 2 стъклени предварително напълнени спринцовки.
Faslodex has 2 pack presentations, either a pack containing 1 glass pre-filled syringe or a pack containing 2 glass pre-filled syringes.
Faslodex съдържа 10% т./об. етанол (алкохол), т.е. до 1 000 mg на доза, еквивалентни на 20 ml бира или 8 ml вино на доза.
Faslodex contains 10% w/v ethanol (alcohol), i.e. up to 1000 mg per dose, equivalent to 20 ml beer or 8 ml wine per dose.
Faslodex трябва да се прилага с повишено внимание при пациенти с леко до умерено чернодробно увреждане (вж. точки 4.2, 4.3 и 5.2).
Faslodex should be used with caution in patients with mild to moderate hepatic impairment (see sections 4.2, 4.3 and 5.2).
Faslodex трябва да се прилага с повишено внимание при пациенти с тежкo бъбречно увреждане (креатининов клирънс <30 ml/мин).
Faslodex should be used with caution in patients with severe renal impairment (creatinine clearance less than 30 ml/min).
Fasturtec 1,5 mg/ml прах и разтворител за концентрат за инфузионен разтвор расбуриказа
Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion rasburicase
Fasturtec 1,5 mg/ml прах и разтворител за концентрат за инфузионен разтвор расбуриказа (rasburicase)
Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion rasburicase
Fasturtec 1,5 mg/ml прах и разтворител за концентрат за инфузионен разтвор.
Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.
Fasturtec е рекомбинантен ензим уратоксидаза, произведен от генетично модифициран щам Saccharomyces cerevisiae.
Fasturtec is a recombinant urate-oxidase enzyme produced by genetically modified Saccharomyces cerevisiae strain.
Fasturtec се прилага еднократно дневно като 30-минутна интравенозна инфузия в 50 ml разтвор на натриев хлорид 9 mg/ml (0,9%) (вж. точка 6.6).
Fasturtec is administered as a once daily 30 minute intravenous infusion in 50 ml of a sodium chloride 9 mg/ml (0.9%) solution (see section 6.6).
Fax +372 6 056 011
Fax: +372 6 056 011
Fax : + 421 2 6920 3926
Fax : + 421 2 3233 4920
Fax: + 33 5 57 55 41 98
Fax: +33 5 57 55 41 98
Fax: + 49 8024 908-1290 e-mail: service@hexal.com
Fax: + 49 8024 908-1290 ail: service@hexal.com
Fax: +44 (0) 1372 461401
Fax: +44 (0)1372 461401
Fax:+31 485 577333
Fax: +31 485 577333
Fc областта на човешкия имуноглобулин G1 се свързва към неонаталния Fc рецептор.
The Fc region of human immunoglobulin G1 binds to the neonatal Fc receptor.
FC подгрупи се базират на избрани популации от пациенти при DUET-1 и DUET-2 и не са предвиждани да представляват окончателни параметри за клинична чувствителност за INTELENCE.
FC subgroups are based on the select patient populations in DUET-1 and DUET-2 and are not meant to represent definitive clinical susceptibility breakpoints for INTELENCE.
Fc фузионен протеин) Всеки флакон ALPROLIX номинално съдържа 250, 500, 1 000, 2 000 или 3 000 IU ефтренонаког алфа.
Each vial of ALPROLIX contains nominally 250, 500, 1000, 2000 or 3000 IU eftrenonacog alfa.
FC чувствителността в клетъчната култура, съотнесена към изходния референтен щам, е изчислена с помощта на PhenoSenseTM (Monogram Biosciences, South San Francisco, California, САЩ).
FC susceptibility in cell culture relative to the wild-type reference was assayed using PhenoSenseTM (Monogram Biosciences, South San Francisco, California, USA)
FCV (щамове 431 и G1 ) ...............................................................................................  2.0 ELISA U.
FCV (431 and G1 strains) ...............................................................................................  2.0 ELISA U.
FD и C Blue 2 (индигокармин, Е132)
FD and C Blue 2 (indigo carmine, E132)
FD&C Син #2 индигокармин алуминиев лак (E132) Fycompa 12 mg филмирани таблетки
FD&C Blue #2 Indigo carmine aluminium lake (E132) Fycompa 12 mg film-coated tablets
Fe LV
FeLV
Feber
Fever
febrilna nevtropenija, limfopenija
Febrile neutropenia, lymphopenia
Febrilná neutropénia
Febrile neutropenia
FEC (5-флуороурацил [500 mg/m2], епирубицин [100 mg/m2], циклофосфамид [600 mg/m2]) са прилагани интравенозно на всеки 3 седмици за три цикъла.
FEC (5-fluorouracil [500 mg/m2], epirubicin [100 mg/m2], cyclophosphamide [600 mg/m2]) were given intravenously every three weeks for 3 cycles.
FEC: 5-флуороурацил, епирубицин, циклофосфамид; TCH: доцетаксел, карбоплатин и трастузумаб, CMH: Cochran–Mantel–Haenszel
FEC: 5-fluorouracil, epirubicin, cyclophosphamide; TCH: docetaxel, carboplatin and trastuzumab, CMH: Cochran–Mantel–Haenszel
FeLV рекомбинантен canarypox вирус (vCP97)........≥ 10 7.2 CCID50
FeLV recombinant Canarypox virus (vCP97) ........ ≥ 10 7.2 CCID50
FeLV/RCP
LEUCOFELIGEN FeLV/RCP
Fem huvudmetaboliter har visat sig vara farmakologiskt inaktiva.
Five major metabolites were detected all having been shown to be pharmacologically inactive.
Fenbenda- zole
Fenbendazole
Fenbendazole има овоциден ефект върху яйцата на нематода.
Fenbendazole has an ovicidal effect on nematode eggs.
Fendrix е бяла млекоподобна суспензия в стъклена предварително напълнена спринцовка (0,5 ml).
Fendrix is a white, milky suspension presented in a glass prefilled syringe (0.5 ml).
Fendrix е ваксина, която предпазва от развитие на хепатит B. Тя се използва при пациенти с бъбречни проблеми:
Fendrix is a vaccine which prevents hepatitis B. It is used for patients with kidney problems:
Fendrix индуцира специфични хуморални антитела срещу повърхностния антиген на вируса на хепатит В (anti-HBs).
Fendrix induces specific humoral antibodies against HBsAg (anti-HBs antibodies).
Fendrix инжекционна суспензия
Fendrix suspension for injection
Fendrix инжекционна суспензия i.m.
Fendrix suspension for injection IM
Fendrix не може да Ви предпази от заболяване ако вече сте се заразили с вируса на хепатит B.
Fendrix may not protect you from being ill if you have already caught the hepatitis B virus.
Fendrix помага на Вашия организъм да създаде своя собствена защита срещу вируса (антитела).
Fendrix helps your body to produce its own protection against the virus (antibodies).
Fendrix се предлага в опаковки по 1 с или без отделна игла и в опаковки по 10 без игли.
Fendrix is available in packs of 1 (with or without a separate needle) and in a pack size of 10 without needles.
Fendrix съдържа две съставки – монофосфорил липид А (нетоксична пречистена мазнина, получена от бактерии) и алуминиев фосфат.
Fendrix contains two things called “MPL” (a non-toxic purified fat derivative from bacteria) and “aluminium phosphate”.
Fendrix трябва да се прилага интрамускулно в делтоидната област.
Fendrix should be injected intramuscularly in the deltoid region.
Fenian Street Dublin 2, Ирландия
Fenian Street Dublin 2, Ireland
Fenitoin
Phenytoin
Feno 145 + Simva 40
Feno 145 +